Trials / Terminated
TerminatedNCT01794234
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis B who have failed antiviral treatment with nucleoside (nucleotide) analogues. Data will be collected from patients treated according to the current Summary of Product Characteristics and local standard of care and regulations during 48 weeks of treatment and 24 weeks of follow-up.
Conditions
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2013-02-18
- Last updated
- 2016-11-02
Locations
9 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT01794234. Inclusion in this directory is not an endorsement.